AnBogen Therapeutics, Inc.

TAIPEI, TAIWAN, August 12, 2025 / EINPresswire.com / -- Primo Biotechnology Co., Ltd., a pioneering developer of Radioligand Drug Conjugates (RDCs), announced today the signing of a Memorandum of Understanding (MoU) with AnBogen Therapeutics, Inc., a prominent biotech firm specializing in novel drug development. The two companies will jointly develop and manufacture an innovative peptide-based radioligand therapeutic, targeting solid tumors diagnosis and treatment — a significant step in advancing precision oncology. This collaboration centers on the application of Peptide-Drug Conjugates (PDCs) technology. AnBogen brings deep expertise in peptide engineering and chelator-linking chemistry, while Primo leads in radiopharmaceutical R&D, offering comprehensive capabilities in drug development, clinical translation, and manufacturing. Guided by a shared commitment to mutual benefit, the two parties will jointly conduct a proof-of-concept (PoC) study to assess the feasibility and clinical potential for treating solid tumors. Dr. Ya-Yao Huang, CEO of Primo Biotech, stated: "Primo is actively building a robust pipeline of radiopharmaceuticals for both diagnostic and therapeutic applications. Given the high technical and regulatory barriers in this field, we are also expanding into radiopharmaceutical CRO and CDMO services. Our goal is to offer a fully integrated, one-stop solution to accelerate the path from innovation to market. This collaboration with AnBogen strengthens our mission and will help speed up the development and commercialization of next-generation therapeutics" Dr. Tsu-An Hsu, CEO of AnBogen, also commented: " Our therapy leverages the high specificity between peptides and tumor receptors to accurately target a wide range of solid tumors. By combining this approach with radioactive isotopes, we can deliver precise treatment directly to cancer cells while minimizing damage to healthy tissue. This innovative method has the potential to significantly improve both the safety and effectiveness of cancer treatment.” Under the MoU, both companies will collaborate on the research and development of novel peptide-based radioligand therapeutics and provide the necessary technical and clinical resources to support the initiative. The initial phase will focus on PoC validation, with future strategic partnership terms with project structure to be determined based on the study’s outcomes. This collaboration reflects both companies’ commitment to advancing precision medicine and reinforces Taiwan’s growing visibility and competitiveness in the global radiopharmaceutical development landscape. About AnBogen Therapeutics, Inc. AnBogen Therapeutics is a clinical-stage biotech company dedicated to designing and developing precision oncology therapies to improve patients' lives. Founded by a group of exceptional scientists committed to bridging the gap between research and clinical development. Our mission is to create breakthrough science that transforms the lives of cancer patients. About Primo Biotechnology Co., Ltd. Primo Biotechnology Co., Ltd., a leading biotech company specializing in the development and manufacturing of radiopharmaceuticals, continues to drive innovation in precision cancer care. With internationally certified facilities and cutting-edge expertise, Primo is committed to advancing molecular imaging and targeted therapy technologies that offer new hope and improved outcomes for cancer patients worldwide. Headquartered in Taipei, Primo collaborates with both domestic and international partners to accelerate progress in precision oncology, leveraging its capabilities in drug development, clinical translation, and GMP manufacturing to support next-generation therapeutics. For more information, please visit https://primobt.com and follow Primo Biotech on Facebook and LinkedIn. Sunny Chen Primo Biotechnology Co, Ltd. +886 919 350 725 email us here Visit us on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). This open-label, multi-center international study plans to enroll 66 patients with proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mCRC to evaluate the safety and preliminary efficacy of the triplet therapy. Enrollment is planned in Taiwan and Australia. Tislelizumab, a PD-1 monoclonal antibody, used in this trial is provided by BeOne Medicines (formerly known as BeiGene). Further details on this collaboration were disclosed by Anbogen in a press release dated September 27, 2024. ABT-301 is an oral HDAC1/2/3 inhibitor. Preclinical studies have shown that it promotes CD8+ cytotoxic T cell infiltration and activity, enhances antigen presentation, and inhibits M-MDSCs cells, effectively modulating the tumor microenvironment and converting "cold tumors" into "hot tumors" to improve the efficacy of immune checkpoint inhibitors. ABT-301 also exhibits pro-apoptotic, anti-angiogenic, and tumor metabolic regulation effects. As a single-molecule, multi-modality anti-cancer agent, ABT-301 aims to enhance tumor treatment when combined with the two antibody drugs. Notably, in a previous Phase 1 monotherapy clinical trial involving 23 participants, ABT-301 did not exhibit neutropenia or cardiac toxicity, which are commonly observed in other HDAC inhibitors—further supporting its suitability for use in combination immunotherapy. Approximately 95% of mCRC patients are pMMR or non-MSI-H types—commonly referred to as "cold tumors"—which respond poorly to current immunotherapies. Only around 5% of patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) "hot tumors" typically benefit from immune checkpoint inhibitors. According to GlobalData, an estimated 370,000 new pMMR/non-MSI-H patients in second-line or later settings are diagnosed annually across the U.S., China, Japan, and the top five European markets (UK, France, Germany, Spain, and Italy), representing a potential market size of USD $9 billion. Anbogen stated that the FDA's IND approval marks a key milestone in the development of ABT-301, demonstrating the safety profile of the triplet therapy and advancing it into clinical stages. The company emphasized that the study targets the majority of patients (over 90%) with poor responses to immunotherapy, aiming to provide a novel treatment option and address this unmet clinical need. Looking ahead, Anbogen will continue to advance the clinical development of ABT-301 while pursuing global licensing and strategic partnerships to accelerate commercialization and market entry. The company is also launching its Series B fundraising to attract strategic partners committed to advancing innovative cancer therapies and global expansion. About Anbogen Therapeutics Anbogen Therapeutics is a clinical-stage biotechnology company committed to developing precision oncology therapies that improve the lives of cancer patients worldwide. The company currently has two core assets: ABT-301, a HDAC1/2/3 inhibitor with immune-modulating capabilities, enhances the tumor microenvironment and boosts immune responses. It significantly improves the efficacy of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC), offering a new treatment pathway for the majority of patients who do not benefit from ICIs. ABT-501 is a novel Peptide Drug Conjugate (PDC) that targets LHRH-receptor tumors using a proprietary delivery system. It has shown strong efficacy and safety in triple-negative breast cancer models, with potential for broader cancer applications. For more information, please visit Anbogen's official website at . SOURCE Anbogen Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TAIPEI, Sept. 27, 2024 /PRNewswire/ -- Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, in patients with mismatch repair–proficient (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in a global Phase II trial. Under the terms of the agreement, BeiGene will supply tislelizumab to Anbogen for the study. In 2020, over 1.9 million new cases of colorectal cancer were diagnosed globally. Immune checkpoint inhibitors (ICIs) have emerged as a primary treatment for metastatic colorectal cancer (mCRC) with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). However, this innovative therapy benefits only a small fraction of patients, as less than 5% of mCRC cases exhibit dMMR/MSI-H. Consequently, there remains a significant unmet need for the 95% of patients with pMMR/MSS tumors, who do not respond to ICIs. ABT-301, a novel HDAC inhibitor, has shown promising safety and pharmacokinetic profiles in a prior Phase 1 study as a single agent. Preclinical studies indicate that ABT-301 enhances the effectiveness of anti-PD-1/anti-PD-L1 therapies by increasing CD8+ cytotoxic T cells and decreasing monocytic myeloid-derived suppressor cells within both the tumor and circulation, and inhibiting angiogenesis. These immune response enhancements may broaden the efficacy of ICIs in colorectal cancer patients. The upcoming Phase II study will investigate the effectiveness of treatment regimens combining ABT-301 and tislelizumab, with and without Bevacizumab, in pMMR/MSS mCRC patients with significant unmet needs. "We are excited to partner with BeiGene to investigate this promising combination therapy," said John Hsu, CEO of Anbogen. "ABT-301 has shown potential in preclinical studies, and we believe that combining it with tislelizumab could provide a new therapeutic option for patients with colorectal cancer." The clinical trial will be conducted in multiple centers and will evaluate the safety, tolerability, and preliminary efficacy of the combination therapy in patients with advanced MSS CRC. The study is expected to begin enrollment in the first quarter of 2025. About Anbogen Anbogen is a clinical-stage biotech company that completed a US$20M Series A in 2024. We are dedicated to developing precision anti-cancer drugs and are committed to R&D innovations to improve the lives of cancer patients around the world. The company was founded by Dr. Joe Shih in response to national science and technology policy. The team has years of experience in new drug development while working at the National Health Research Institutes and in the biopharma industry. Currently, there are two clinical-stage assets being developed. ABT-101 is being investigated in non-small cell lung cancer (NSCLC) patients who harbor HER2 exon20 insertion mutations, and ABT-301 and being investigated in pMMR/MSS mCRC patients in combination with anti-PD-1. For more information, please visit . SOURCE Anbogen Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED